1-2 of 2
Marzia Varettoni
Close
Sort by
Journal Articles

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Clinical Trials & Observations
Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro, Annalisa Chiarenza, Marta Coscia, Stefania Ciolli, Gianluigi Reda, Luca Laurenti, Marzia Varettoni, Roberta Murru, Claudia Baratè, Paolo Sportoletti, Antonino Greco, Chiara Borella, Valentina Rossi, Marina Deodato, Annalisa Biagi, Giulia Zamprogna, Angelo Curto Pelle, Gianfranco Lapietra, Candida Vitale, Francesca Morelli, Ramona Cassin, Alberto Fresa, Chiara Cavalloni, Massimiliano Postorino, Claudia Ielo, Roberto Cairoli, Francesco Di Raimondo, Marco Montillo, Giovanni Del Poeta
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5490–5500.
https://doi.org/10.1182/bloodadvances.2021004824
Published: 2021
Includes: Supplemental data
Journal Articles

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Clinical Trials & Observations
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Stephen Opat, Shirley D'Sa, Roger G. Owen, Gavin Cull, Stephen Mulligan, Jaroslaw Czyz, Jorge J. Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella Mesa, Miquel Granell Gorrochategui, Dipti Talaulikar, Pier Luigi Zinzani, Elham Askari, Sebastian Grosicki, Albert Oriol, Simon Rule, Janusz Kloczko, Alessandra Tedeschi, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y. Chan, Jan Michel, Jingjing Schneider, Ziwen Tan, Aileen Cohen, Jane Huang, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (23): 6009–6018.
https://doi.org/10.1182/bloodadvances.2020003010
Published: 2020
Includes: Supplemental data